Swedish pharmaceutical giant acquires Sanofi’s inhalation drug business and North West plant in £45m deal

Swedish pharmaceutical firm Recipharm has struck a deal with drugmaker Sanofi to buy its contract inhalation drug business and manufacturing plant in the North West for £45m.

The 125,000 sq m site at Holmes Chapel is where Sanofi makes inhalers and nasal sprays for contract clients.

The deal is expected to close in the fourth quarter of 2018, when Recipharm will add the plant’s 450 employees.

Recipharm said the acquisition will add scale to its business and provide access to new customers and higher margin specialised technologies.

It also said the purchase of the manufacturing centre, one of the leading sites of its type in Europe, provides it with a solid platform to take further advantage of the growing respiratory drug market.

Thomas Eldered, CEO of Recipharm, said: “Holmes Chapel brings Recipharm an ideal opportunity to accelerate its offering to customers with access to novel of respiratory products. As an already successful CMO with several clients, we look forward to introducing new contracts to Holmes Chapel by utilising our growing franchise in development services.

“Treatments for asthma and chronic obstructive pulmonary disease (COPD) are growing at a fast rate and we see many opportunities. The experienced management team and staff have already successfully attracted new customers and we look forward to building on this from the well invested facility.”

Click here to sign up to receive our new South West business news...
Close